https://www.lyfegen.com/pharma https://www.lyfegen.com https://www.lyfegen.com/about-us https://www.lyfegen.com/career-old https://www.lyfegen.com/blog https://www.lyfegen.com/demo https://www.lyfegen.com/payers/ara https://www.lyfegen.com/pharma/library https://www.lyfegen.com/pharma/simulator https://www.lyfegen.com/payers/retro https://www.lyfegen.com/payers/rmas https://www.lyfegen.com/payers-providers https://www.lyfegen.com/pharma/ara https://www.lyfegen.com/pharmarabatte https://www.lyfegen.com/trendreportq2 https://www.lyfegen.com/medicaid https://www.lyfegen.com/annual-report https://www.lyfegen.com/lyfegen-2025 https://www.lyfegen.com/epaoriginal https://www.lyfegen.com/simon-landing-page-draft https://www.lyfegen.com/q1-trends-report-2025 https://www.lyfegen.com/career https://www.lyfegen.com/q2-trends-report-2025 https://www.lyfegen.com/q3-trends-report-2025 https://www.lyfegen.com/medicaid-copy https://www.lyfegen.com/annual-report-2025 https://www.lyfegen.com/lyfegen-2026 https://www.lyfegen.com/pharma/aicco https://www.lyfegen.com/aicco https://www.lyfegen.com/gcf https://www.lyfegen.com/contact-us https://www.lyfegen.com/job-post/account-executive-canada https://www.lyfegen.com/job-post/customer-operations-specialist---german-speaker https://www.lyfegen.com/job-post/spontaneous-application https://www.lyfegen.com/post/a-big-win-for-value-based-care-medicare-can-now-negotiate-some-drug-prices-e3546 https://www.lyfegen.com/post/a-bright-new-chapter-in-uk-healthcare-how-ai-driven-reform-will-transform-drug-pricing-and-access https://www.lyfegen.com/post/a-fable-of-the-blue-bird-and-lyfegens-wise-owls https://www.lyfegen.com/post/a-novel-medicaid-model-to-pay-for-latest-gene-therapies https://www.lyfegen.com/post/a-promising-sickle-cell-cure-is-almost-here-what-about-the-money-to-pay-for-it https://www.lyfegen.com/post/accelerating-drug-access-lyfegens-innovative-drug-contracting-simulator https://www.lyfegen.com/post/adding-a-medicare-part-e-benefit-to-pay-for-cell-and-gene-therapies https://www.lyfegen.com/post/after-accelerated-drug-approval-value-based-drug-pricing-does-the-work-of-real-world-data-collection https://www.lyfegen.com/post/after-accelerated-drug-approval-value-based-pricing-does https://www.lyfegen.com/post/big-win-value-based-care-medicare-can-now-negotiate-some https://www.lyfegen.com/post/biosimilars-appear-ready-for-prime-time-in-the-u-s-as-reimbursement-is-increasingly-value-based https://www.lyfegen.com/post/biosimilars-appear-ready-prime-time-us-reimbursement-increasingly https://www.lyfegen.com/post/bluebird-bios https://www.lyfegen.com/post/brazils-key-manufacturers-and-payers https://www.lyfegen.com/post/breaking-news-additional-funding https://www.lyfegen.com/post/canada-investing-in-rwe-for-rare-diseases https://www.lyfegen.com/post/cell-and-gene-therapy-approvals-will-target-much-larger-populations-by-end-of-decade https://www.lyfegen.com/post/changes-in-medicaids-best-price-rule-likely-to-boost-value-based-purchasing-agreements https://www.lyfegen.com/post/clinical-trial-outcomes-the-key-to-driving-drug-pricing-and-market-access https://www.lyfegen.com/post/cma-and-lyfegen https://www.lyfegen.com/post/como-se-esta-preparando-espana-para-la-nueva-normativa-europea https://www.lyfegen.com/post/conozca-a-david-duro-nuestro-nuevo-vicepresidente-de-ventas-y-desarrollo-de-negocio-un-lider-que-conecta-con-sus-clientes-y-les-ofrece-soluciones-eficaces https://www.lyfegen.com/post/could-a-value-based-purchasing-agreement-with-the-u-s-centers-for-medicaid-and-medicare-services-have-saved-aduhelm https://www.lyfegen.com/post/do-drug-companies-really-want-more-competition-value-based https://www.lyfegen.com/post/do-drug-companies-really-want-more-competition-value-based-purchasing-puts-them-to-the-test https://www.lyfegen.com/post/drug-contracting-bridging-the-gap-between-value-and-cost https://www.lyfegen.com/post/drug-makers-and-payers-will-leverage-ira-maximum-fair-prices https://www.lyfegen.com/post/drug-market-access-strategies-in-2024-key-considerations-for-pharma-companies https://www.lyfegen.com/post/empowering-change-through-code-denisa-filip-joins-lyfegen https://www.lyfegen.com/post/envisioning-solutions-that-solve-meaningful-real-world-problems-meet-andrei-cantea-our-new-visionary-senior-product-designer https://www.lyfegen.com/post/exclusive-interview-with-girisha-fernando-at-the-launch-of-lyfegens-value-based-agreement-library https://www.lyfegen.com/post/explorando-contratos-basados-en-el-valor-acuerdos-publicos-destacados-en-canada-dinamarca-y-brasil https://www.lyfegen.com/post/exploring-value-based-contracts-featured-public-agreements-in-canada-denmark-and-brazil https://www.lyfegen.com/post/fda-launches-a-new-program-to-speed-patient-access https://www.lyfegen.com/post/federal-trade-commission-inquiry-could-eventually-lead-overhaul https://www.lyfegen.com/post/federal-trade-commission-inquiry-could-eventually-lead-to-overhaul-of-prescription-drug-rebate-system https://www.lyfegen.com/post/finding-novel-ways-to-pay-for-new-obesity-drugs https://www.lyfegen.com/post/finding-the-right-insulin-products-for-payers-to-cover https://www.lyfegen.com/post/gene-therapies-negotiating-the-priceless-insights-from-the-lyfegen-2024-drug-contracting-trends-report https://www.lyfegen.com/post/girisha-fernando-talks-to-kantonsspital-baden-ag-about-value-focused-reimbursement-of-drugs-based-on-the-outcomes-for-patients-in-switzerland-and-globally-duplicate-1 https://www.lyfegen.com/post/health-technology-assessment-will-inform-medicare-drug-price-negotiations https://www.lyfegen.com/post/healthcare-providers-hold-real-world-evidence-about-a-drugs-value-how-to-convince-them-to-share-the-data https://www.lyfegen.com/post/healthcare-providers-hold-real-world-evidence-drugs-value https://www.lyfegen.com/post/hello-to-our-new-team-member-meet-efficacy-expert-anca-marin https://www.lyfegen.com/post/how-could-donald-trump-change-us-healthcare https://www.lyfegen.com/post/how-far-would-you-go-to-save-your-child https://www.lyfegen.com/post/how-gene-therapies-are-reshaping-patient-outcomes-and-payer-expectations https://www.lyfegen.com/post/how-lyfegens-value-based-contracting-platform-was-inspired-by-airbnb https://www.lyfegen.com/post/how-overcome-hurdles-implement-value-based-pricing-lyfegenhealth https://www.lyfegen.com/post/how-spain-is-preparing-for-europes-new-regulation https://www.lyfegen.com/post/how-technology-is-transforming-drug-rebate-management https://www.lyfegen.com/post/how-to-choose-the-right-drug-rebate-management-solution https://www.lyfegen.com/post/how-to-overcome-hurdles-to-implement-value-based-pricing https://www.lyfegen.com/post/how-value-based-contracts-are-redefining-drug-pricing-through-clinical-trials https://www.lyfegen.com/post/icer-hero-or-villain-in-the-story-of-value-based-drug-pricing https://www.lyfegen.com/post/if-gene-therapies-in-the-diabetes-space-gain-approval-reimbursement-challenges-will-reach-a-critical-juncture https://www.lyfegen.com/post/indication-specific-pricing-make-inroads-us-lyfegenhealth https://www.lyfegen.com/post/indication-specific-pricing-to-make-inroads-in-the-u-s https://www.lyfegen.com/post/industry-experts-agree-outcome-based-contracting-is-vital-to-the-future-of-cell-and-gene-therapies https://www.lyfegen.com/post/is-this-new-drug-worth-the-cost-payers-decide-using-value-based-purchasing-agreements https://www.lyfegen.com/post/iso27001 https://www.lyfegen.com/post/italys-healthcare-reform-key-takeaways-for-pharma-payers-and-market-access-strategies https://www.lyfegen.com/post/jason-helgerson-joins-lyfegen https://www.lyfegen.com/post/joao-marques-gomes-joins-lyfegen-advisory-board https://www.lyfegen.com/post/johnsonandjohnson https://www.lyfegen.com/post/join-lyfegen-at-ppma https://www.lyfegen.com/post/join-lyfegens-cfo-michel-mohler-on-june-18th-at-the-basel-area-business-innovation-and-deloitte-dayone-experts-webinar https://www.lyfegen.com/post/keeping-our-users-happy-everyday-meet-liubov-our-new-quality-assurance-qa-engineer https://www.lyfegen.com/post/la-reforma-de-medicare-parte-d-en-2025 https://www.lyfegen.com/post/leveraging-clinical--and-cost-effectiveness-data-to-inform-drug-pricing-and-reimbursement https://www.lyfegen.com/post/leveraging-clinical-and-cost-effectiveness-data-to-inform-drug-pricing-and-reimbursement https://www.lyfegen.com/post/linking-drug-prices-to-success-the-power-of-outcome-based-agreements-in-the-ozempic-era https://www.lyfegen.com/post/lyfegen-and-eversana-collaborate-to-revolutionize-drug-pricing-and-access-with-ai-driven-insights https://www.lyfegen.com/post/lyfegen-and-switzerlands-egk-insurance-partner-to-reduce-prices-for-high-cost-drugs https://www.lyfegen.com/post/lyfegen-at-innopeaks https://www.lyfegen.com/post/lyfegen-co-founders-announce-leadership-roles-with-the-newly-established-european-association-of-value-based-healthcare https://www.lyfegen.com/post/lyfegen-erhalt-8-millionen-dollar-um-arzneimittelpreise-zu-senken-und-patienten-den-zugang-zu-lebensrettenden-medikamenten-zu-erleichtern https://www.lyfegen.com/post/lyfegen-is-iso-certified https://www.lyfegen.com/post/lyfegen-kpmg-whitepaper https://www.lyfegen.com/post/lyfegen-launches-the-worlds-largest-database-of-value-based-drug-agreements https://www.lyfegen.com/post/lyfegen-raises-8-million https://www.lyfegen.com/post/lyfegen-raises-8-million-to-drive-down-drug-costs-and-help-patients-access-life-saving-medications https://www.lyfegen.com/post/lyfegen-raises-chf-750000-in-seed-capital https://www.lyfegen.com/post/lyfegen-secures-additional-chf-5-million-in-series-a-funding-to-scale-its-drug-rebate-management-platform-globally https://www.lyfegen.com/post/lyfegen-supports-sustainable-development-goals https://www.lyfegen.com/post/lyfegen-und-die-schweizerische-krankenversicherung-egk-gesundheitskasse-kooperieren-bei-der-senkung-der-preise-fur-teure-medikamente https://www.lyfegen.com/post/lyfegen-welcomes-antti-as-product-owner https://www.lyfegen.com/post/managing-the-cost-of-novel-non-opioid-pain-medications https://www.lyfegen.com/post/medicare-needs-authority-to-negotiate-drug-prices-to-support-its-value-based-healthcare-strategy https://www.lyfegen.com/post/medicare-part-d-redesign-could-reboot-u-s-prescription-drug-market-for-cancer-drugs-making-pricing-more-value-based https://www.lyfegen.com/post/medicare-part-d-redesign-could-reboot-us-prescription-drug https://www.lyfegen.com/post/medicare-part-ds-2025-overhaul https://www.lyfegen.com/post/meet-david-duro-our-new-vp-of-sales-business-development-a-leader-who-connects-with-his-customers-and-helps-them-find-powerful-solutions https://www.lyfegen.com/post/meet-olga-dragos-our-newest-key-member-and-efficiency-champion https://www.lyfegen.com/post/meet-our-new-in-house-detective-hello-to-alina-bratu https://www.lyfegen.com/post/michael-porter-vbhc https://www.lyfegen.com/post/mindful-leadership https://www.lyfegen.com/post/new-net-cost-reimbursement-models-may-stimulate-u-s-biosimilar-uptake https://www.lyfegen.com/post/nico-mros-named-lyfegens-chief-customer-experience-officer https://www.lyfegen.com/post/nlhealthservices-ceo-interview https://www.lyfegen.com/post/one-time-cell-and-gene-therapies-offer-promises-of-cures-but-payment-challenges-remain https://www.lyfegen.com/post/ongoing-debate-around-glp-1-drug-coverage https://www.lyfegen.com/post/preparing-for-medicare-part-d-redesign-in-2025-are-you-ready https://www.lyfegen.com/post/principales-fabricantes-y-pagadores-en-brasil https://www.lyfegen.com/post/professor-jens-gruger-phd-joins-lyfegen-advisory-board https://www.lyfegen.com/post/rare-disease-therapies-and-the-case-for-outcomes-based-agreements https://www.lyfegen.com/post/re-dosable-gene-therapy-vyjuveks-initially-successful-launch-offers-lessons https://www.lyfegen.com/post/rethinking-medicine-payments-with-smarter-drug-rebate-management-solutions https://www.lyfegen.com/post/sickle-cell-disease-gene-therapies-are-here-but-how-is-society-going-to-pay-for-them https://www.lyfegen.com/post/simon-amstutz-joins-lyfegen https://www.lyfegen.com/post/spain-reducing-unnecessary-care-and-improving-hta-education https://www.lyfegen.com/post/study-approval-to-reimbursement-times-in-the-us-vs-europe https://www.lyfegen.com/post/study-out-of-pocket-drug-costs-increasing-5-8-per-year https://www.lyfegen.com/post/swiss-healthcare-change https://www.lyfegen.com/post/switzerland-improving-the-fast-track-process-and-anti-migraine-drugs https://www.lyfegen.com/post/switzerland-innovation-leader https://www.lyfegen.com/post/sympany https://www.lyfegen.com/post/tailoring-biosimilar-coverage-policies-to-the-client https://www.lyfegen.com/post/tech-genius-dima-joins-lyfegen https://www.lyfegen.com/post/the-biosecure-act-passes-the-house https://www.lyfegen.com/post/the-cost-of-innovation-budget-impact-of-gene-therapy-for-sickle-cell-disease-on-medicaid-plans https://www.lyfegen.com/post/the-effect-of-value-based-drug-pricing-on-patient-health-outcomes-more-of-whats-needed-efficacy-access-and-affordability https://www.lyfegen.com/post/the-health-and-social-consortium-of-catalonia-to-develop-new-value-based-purchasing-models https://www.lyfegen.com/post/the-importance-of-working-with-johnson-johnson-an-interview-with-our-lyfegen-ceo-founder-girisha-fernando https://www.lyfegen.com/post/the-joint-clinical-assessment-jca-a-new-era-for-market-access-strategies-in-the-eu https://www.lyfegen.com/post/the-role-of-value-base-care-in-patient-access https://www.lyfegen.com/post/the-shift-to-financially-optimized-clinical-trials https://www.lyfegen.com/post/the-tech-team-keeps-growing-welcome-to-the-lyfegen-team-analytical-superstar-pavlo-duplicate-1 https://www.lyfegen.com/post/the-uphill-battle-for-value-based-drug-pricing-agreements-may-be-coming-to-an-end https://www.lyfegen.com/post/transforming-healthcare-access-in-canada-ina-hasanis-vision-at-lyfegen https://www.lyfegen.com/post/trump-healthcare-executive-orders https://www.lyfegen.com/post/u-s-department-of-health-and-human-services-innovation-center-revamps-value-based-payment-models https://www.lyfegen.com/post/uk-standardizing-the-economic-evaluation-of-ai-tech https://www.lyfegen.com/post/uphill-battle-value-based-drug-pricing-agreements-may-coming https://www.lyfegen.com/post/us-department-health-human-services-innovation-center-revamps https://www.lyfegen.com/post/value-based-drug-agreements-are-easier-when-drug-manufacturers-and-payers-follow-fda-communication-guidelines https://www.lyfegen.com/post/value-based-drug-agreements-easier-when-manufacturers-payers https://www.lyfegen.com/post/value-based-insurance-design-is-ready-for-primetime https://www.lyfegen.com/post/value-based-pricing-vs-best-price-medicaids-best-price-problem https://www.lyfegen.com/post/value-based-pricing-vs-best-price-medicaids-problem-lyfegenhealth https://www.lyfegen.com/post/welcome-simonfarrow https://www.lyfegen.com/post/welcome-to-lyfegen-tech-guru-andrei https://www.lyfegen.com/post/welcome-to-the-lyfegen-team-mastermind-developer-thungu https://www.lyfegen.com/post/welcome-to-the-lyfegen-team-tech-genius-giancarlo https://www.lyfegen.com/post/what-is-value-based-contracting-with-lyfegen https://www.lyfegen.com/post/what-will-it-take-to-advance-value-based-pharmaceutical-contracts https://www.lyfegen.com/post/whichever-instrument-used-qaly-or-non-qaly-payers-make-evidence-based-coverage-decisions https://www.lyfegen.com/post/who-does-better-assessing-value-based-drug-price-europe https://www.lyfegen.com/post/who-does-it-better-assessing-a-value-based-drug-price-in-europe-vs-the-us https://www.lyfegen.com/post/why-q1-is-critical-for-pharma-rebate-management https://www.lyfegen.com/case-studies-white-papers/2024-in-review-are-drug-access-agreement-trends-going-the-right-way https://www.lyfegen.com/case-studies-white-papers/ai-will-decide-who-gets-access-why-drug-contracting-is-becoming-pharmas-most-strategic-capability https://www.lyfegen.com/case-studies-white-papers/innovative-rebate-management-in-oncology-drug-budgets https://www.lyfegen.com/case-studies-white-papers/problemas-y-necesidades-en-la-gestion-de-acuerdos-farmaceuticos-meas https://www.lyfegen.com/case-studies-white-papers/pt-hospitals https://www.lyfegen.com/case-studies-white-papers/pt-manufacturers https://www.lyfegen.com/case-studies-white-papers/revolutionizing-drug-access-in-portugal-scaling-outcome-based-agreements-with-digital-innovation https://www.lyfegen.com/case-studies-white-papers/rewriting-the-playbook-how-ai-can-accelerate-market-access-pricing-decisions https://www.lyfegen.com/case-studies-white-papers/swiss-manufacturers https://www.lyfegen.com/case-studies-white-papers/swiss-payers